Novo Nordisk A/S [NYSE: NVO] plunged by -$2.09 during the normal trading session on Thursday and reaching a high of $139.04 during the day while it closed the day at $138.89. The company report on March 14, 2023 that Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Novo Nordisk has been working to identify a sustainable approach to reduce insulin costs for patients that addresses changes in health policy and market shifts.
Lower list prices build on long-standing history of affordability initiatives already in place which can be accessed at NovoCare.com.
Novo Nordisk A/S stock has also loss -2.21% of its value over the past 7 days. However, NVO stock has inclined by 4.55% in the 3 months of the year. Over the past six months meanwhile, it has gained 32.23% and gained 2.62% year-on date.
The market cap for NVO stock reached $245.18 billion, with 2.28 billion shares outstanding and 1.17 billion shares in the current float. Compared to the average trading volume of 1.43M shares, NVO reached a trading volume of 2987060 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Novo Nordisk A/S [NVO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVO shares is $151.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVO stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Novo Nordisk A/S shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 15, 2022. The new note on the price target was released on June 28, 2022, representing the official price target for Novo Nordisk A/S stock.
The Average True Range (ATR) for Novo Nordisk A/S is set at 2.79, with the Price to Sales ratio for NVO stock in the period of the last 12 months amounting to 9.74. The Price to Book ratio for the last quarter was 26.61, with the Price to Cash per share for the same quarter was set at 1.90. Price to Free Cash Flow for NVO in the course of the last twelve months was 41.61 with Quick ratio for the last quarter at 0.70.
NVO stock trade performance evaluation
Novo Nordisk A/S [NVO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.21. With this latest performance, NVO shares dropped by -2.84% in over the last four-week period, additionally plugging by 32.23% over the last 6 months – not to mention a rise of 35.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVO stock in for the last two-week period is set at 44.11, with the RSI for the last a single of trading hit 38.50, and the three-weeks RSI is set at 48.11 for Novo Nordisk A/S [NVO]. The present Moving Average for the last 50 days of trading for this stock 139.85, while it was recorded at 140.93 for the last single week of trading, and 118.98 for the last 200 days.
Novo Nordisk A/S [NVO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novo Nordisk A/S [NVO] shares currently have an operating margin of +42.06 and a Gross Margin at +82.50. Novo Nordisk A/S’s Net Margin is presently recorded at +31.38.
Return on Total Capital for NVO is now 72.02, given the latest momentum, and Return on Invested Capital for the company is 57.99. Return on Equity for this stock inclined to 72.00, with Return on Assets sitting at 25.48. When it comes to the capital structure of this company, Novo Nordisk A/S [NVO] has a Total Debt to Total Equity ratio set at 30.88. Additionally, NVO Total Debt to Total Capital is recorded at 23.60, with Total Debt to Total Assets ending up at 10.69. Long-Term Debt to Equity for the company is recorded at 29.13, with the Long-Term Debt to Total Capital now at 22.25.
Reflecting on the efficiency of the workforce at the company, Novo Nordisk A/S [NVO] managed to generate an average of $1,020,812 per employee. Receivables Turnover for the company is 3.79 with a Total Asset Turnover recorded at a value of 0.81.Novo Nordisk A/S’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.90.
Earnings per share (EPS) analysis for Novo Nordisk A/S [NVO] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novo Nordisk A/S go to 2.80%.
Novo Nordisk A/S [NVO]: Insider Ownership positions
There are presently around $20,406 million, or 8.40% of NVO stock, in the hands of institutional investors. The top three institutional holders of NVO stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 12,604,288, which is approximately -17.667% of the company’s market cap and around 26.40% of the total institutional ownership; JENNISON ASSOCIATES LLC, holding 11,454,782 shares of the stock with an approximate value of $1.59 billion in NVO stocks shares; and FISHER ASSET MANAGEMENT, LLC, currently with $1.25 billion in NVO stock with ownership of nearly -3.288% of the company’s market capitalization.
Positions in Novo Nordisk A/S stocks held by institutional investors increased at the end of Wednesday and at the time of the Wednesday reporting period, where 494 institutional holders increased their position in Novo Nordisk A/S [NYSE:NVO] by around 15,259,122 shares. Additionally, 416 investors decreased positions by around 8,440,628 shares, while 197 investors held positions by with 123,219,397 shares. The mentioned changes placed institutional holdings at 146,919,147 shares, according to the latest SEC report filing. NVO stock had 196 new institutional investments in for a total of 3,697,580 shares, while 53 institutional investors sold positions of 811,779 shares during the same period.